About the special issue
In contrast to areas generally attacked in pharmaceutical development, a brief overview of health care expenditures shows that most of the health care costs come from inadequate treatment of common chronic diseases that cluster together and are significantly impacted by metabolic function. These conditions include type 2 diabetes, fatty liver disease, cardiovascular disease, and neurodegeneration including dementia.
There are currently no effective approaches to treat these overlapping disease states which until recently have seemed a natural consequence of aging. A new paradigm of drug discovery is suggested by molecular connections between common metabolic diseases.
Guest advisor and Key Opinion leader Dr Jerry Colca (Cirius Therapeutics, USA) has teamed up with Expert Opinion on Investigational Drugs in this special issue that brings together various approaches seeking to impact the metabolic dysfunctions that fuel the spectrum of chronic disease.
This collection will emphasize the discovery and evaluation of investigational drugs and drug combinations that might serve a broader purpose. This special interest volume will include agents that were initially targeted to treat specific inflammatory diseases, including type 2 diabetes, which might produce unexpected advantages for maintaining human health in response to environmental challenges.
There is no limitation on which disease states are targeted by investigational treatments. Topics may include:
• Reducing metabolic inflexibility
• Harnessing the power of immunomodulation
• Reducing neuroinflammation.
The issue welcomes authors to submit relevant editorials, reviews, interviews, and original research. If you are interested in contributing, or would like to learn more, then please reach out to the Commissioning Editor, Ryan Gilroy, who will be happy to assist.